Literature DB >> 6594324

The activity of enoxacin against clinical bacterial isolates in comparison with that of five other agents, and factors affecting that activity.

D S Reeves, M J Bywater, H A Holt.   

Abstract

The activity of enoxacin against 362 clinical bacterial isolates in comparison with norfloxacin, nalidixic acid, ampicillin, latamoxef (moxalactam) and gentamicin was tested by an agar dilution method. Typical MICs for enterobacteria lay between 0.12 and 1.0 mg/l. Enterobacter spp. and Serratia spp. tended to be more resistant. Enoxacin was also active against Pseudomonas aeruginosa (mean MIC 0.5 mg/l) and highly active against fastidious Gram-negative aerobes. Typical MICs for Staphylococcus aureus were 1-2 mg/l while streptococci were more resistant (16-32 mg/l). Enoxacin had no useful activity against Bacteroides fragilis and Clostridium perfringens. Enoxacin was generally more active at pH 8 than pH 6, and in broth than in urine. It was bactericidal in its action. Daily serial passage from growth in broth containing enoxacin caused decreased sensitivity which was limited to four- to 16-fold greater than the original MIC. Enoxacin was about half as active as norfloxacin against enterobacteria, equally active against staphylococci, and some two to four times less active against streptococci.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6594324     DOI: 10.1093/jac/14.suppl_c.7

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

1.  In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.

Authors:  D Gargallo-Viola; M Esteve; S Llovera; X Roca; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Treatment of uncomplicated urogenital gonorrhoea in women with a single dose of enoxacin.

Authors:  M J Tegelberg-Stassen; A H van der Willigen; J C van der Hoek; J H Wagenvoort; H J van Vliet; B van Klingeren; T van Joost; M F Michel; E Stolz
Journal:  Eur J Clin Microbiol       Date:  1986-08       Impact factor: 3.267

3.  Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.

Authors:  D Gargallo-Viola; M Esteve; M Moros; R Coll; M A Xicota; C de Andres; R Roser; J Guinea
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

4.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

5.  In vitro induction of ciprofloxacin resistance in coagulase-negative staphylococci.

Authors:  J W Hartley; B A Oppenheim
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

6.  Effect of enoxacin on colonic microflora of healthy volunteers.

Authors:  C Edlund; A Lidbeck; L Kager; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

7.  Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.

Authors:  H Thadepalli; S V Gollapudi; S K Chuah
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

8.  Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus.

Authors:  R J Davidson; G G Zhanel; R Phillips; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Pharmacokinetics and bioavailability of intravenous-to-oral enoxacin in elderly patients with complicated urinary tract infections.

Authors:  C R Marchbanks; D J Mikolich; K H Mayer; S H Zinner; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

Review 10.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.